Published in Circ Cardiovasc Qual Outcomes on November 19, 2013
Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012. J Am Heart Assoc (2014) 0.93
Aspirin for primary prevention of cardiovascular disease. Thromb J (2015) 0.82
Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLoS One (2016) 0.81
Validation of low-dose aspirin prescription data in The Health Improvement Network: how much misclassification due to over-the-counter use? Pharmacoepidemiol Drug Saf (2015) 0.79
Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk. Cardiovasc Ther (2016) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Universal definition of myocardial infarction. Circulation (2007) 11.69
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res (2004) 4.00
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension (2007) 2.90
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer (2003) 1.98
Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med (2007) 1.95
Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol (2004) 1.95
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol (2006) 1.90
Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. Pharmacoepidemiol Drug Saf (2011) 1.85
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther (2006) 1.77
Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res (2005) 1.64
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med (2006) 1.62
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum (2010) 1.61
Complete myocardial revascularization: between myth and reality. Eur Heart J (2005) 1.55
Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies. JACC Cardiovasc Interv (2013) 1.54
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) (2009) 1.52
Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J (2005) 1.47
The adequacy of myocardial revascularization in patients with multivessel coronary artery disease. Int J Cardiol (2013) 1.45
Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. Thromb Haemost (2013) 1.43
Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause (2006) 1.43
Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am Heart J (2004) 1.41
Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol (2003) 1.39
Incidence and risk factors for atrial fibrillation in patients with newly diagnosed heart failure. J Cardiovasc Med (Hagerstown) (2016) 1.38
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J (2004) 1.34
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J (2011) 1.34
The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proc Natl Acad Sci U S A (2006) 1.32
Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer. Pharmacoepidemiol Drug Saf (2009) 1.30
Recommendations for the management of patients after heart valve surgery. Eur Heart J (2005) 1.29
At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol (2005) 1.27
Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther (2011) 1.26
Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys (2012) 1.24
Adipose tissue-derived stem cells: characterization and potential for cardiovascular repair. Arterioscler Thromb Vasc Biol (2009) 1.23
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J (2011) 1.23
Morbidity associated with sleep disorders in primary care: a longitudinal cohort study. Prim Care Companion J Clin Psychiatry (2007) 1.23
Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids (2008) 1.22
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology (2006) 1.21
Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions. J Am Coll Cardiol (2006) 1.20
Cellular and molecular mechanisms of vascular injury in diabetes--part I: pathways of vascular disease in diabetes. Vascul Pharmacol (2011) 1.14
Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care (2012) 1.12
Nonsteroidal anti-inflammatory drugs and risk of lung cancer. Int J Cancer (2007) 1.12
Non-coronary atherosclerosis. Eur Heart J (2014) 1.11
Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol (2004) 1.11
Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.11
Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis (2009) 1.08
Docosahexaenoic acid ethyl esters ineffective? Proc Natl Acad Sci U S A (2013) 1.07
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis (2012) 1.05
Respiratory medications and the risk of cardiac arrhythmias. Epidemiology (2005) 1.05
Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail (2011) 1.03
Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology (2011) 1.03
Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res (2009) 1.01
Adipose tissue: a new source for cardiovascular repair. J Cardiovasc Med (Hagerstown) (2010) 1.00
Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease. Vascul Pharmacol (2012) 1.00
Homocysteine induces VCAM-1 gene expression through NF-kappaB and NAD(P)H oxidase activation: protective role of Mediterranean diet polyphenolic antioxidants. Am J Physiol Heart Circ Physiol (2007) 1.00
Breast cancer risk among users of antidepressant medications. Epidemiology (2005) 0.99
Age-dependent impairment of number and angiogenic potential of adipose tissue-derived progenitor cells. Eur J Clin Invest (2010) 0.98
Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost (2014) 0.96
Bedside monitoring of antiplatelet therapy for coronary stenting. N Engl J Med (2013) 0.95
Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care. Drug Saf (2011) 0.94
Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models. Atherosclerosis (2005) 0.94
Magnetocardiography: current status and perspectives. Part II: Clinical applications. Ital Heart J (2002) 0.94
Inducible nitric oxide synthase and heme oxygenase-1 in rat heart: direct effect of chronic exposure to hypoxia. Ann Clin Lab Sci (2003) 0.93
Left ventricular wall stress as a direct correlate of cardiomyocyte apoptosis in patients with severe dilated cardiomyopathy. Am Heart J (2003) 0.92
Hepatocyte growth factor/Met gene transfer in cardiac stem cells--potential for cardiac repair. Basic Res Cardiol (2010) 0.92
Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. Thromb Haemost (2002) 0.91
Optical coherence tomography accurately identifies intermediate atherosclerotic lesions--an in vivo evaluation in the rabbit carotid artery. Atherosclerosis (2006) 0.91
Transplantation of mesenchymal cells rejuvenated by the overexpression of telomerase and myocardin promotes revascularization and tissue repair in a murine model of hindlimb ischemia. Circ Res (2013) 0.90
Cancer incidence in a general population of asthma patients. Pharmacoepidemiol Drug Saf (2006) 0.90
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol (2007) 0.90
Cellular and molecular mechanisms of vascular injury in diabetes--part II: cellular mechanisms and therapeutic targets. Vascul Pharmacol (2011) 0.88
Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int (2009) 0.88
PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium. Cardiovasc Res (2009) 0.88
"In vivo" imaging of atherosclerosis. Atherosclerosis (2012) 0.88
Gallbladder disease in the general population: association with cardiovascular morbidity and therapy. Pharmacoepidemiol Drug Saf (2007) 0.87
Controversies in COX-2 selective inhibition. J Rheumatol (2002) 0.86
Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide (2006) 0.86
Nutraceuticals and prevention of atherosclerosis: focus on omega-3 polyunsaturated fatty acids and Mediterranean diet polyphenols. Cardiovasc Ther (2010) 0.86
Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J Biol Chem (2005) 0.86
Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost (2012) 0.86
Inverse association between carotid intima-media thickness and the antioxidant lycopene in atherosclerosis. Am Heart J (2002) 0.86
Guide and Position of the International Society of Nutrigenetics/Nutrigenomics on Personalised Nutrition: Part 1 - Fields of Precision Nutrition. J Nutrigenet Nutrigenomics (2016) 0.85
Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes. Thromb Haemost (2012) 0.85
Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf (2011) 0.85
Omega-3 fatty acids, inflammation and angiogenesis: nutrigenomic effects as an explanation for anti-atherogenic and anti-inflammatory effects of fish and fish oils. J Nutrigenet Nutrigenomics (2007) 0.85
Sodium-hydrogen exchangers (NHE) in human cardiovascular diseases: interfering strategies and their therapeutic applications. Vascul Pharmacol (2013) 0.85